SuperworthMaxcyte market cap MXCT
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $144.5M
- Highest close in our data
- $1.4B
- Sep 2021
Maxcyte is worth $144.5M at the close on Oct 23, 2026, at $1.40 a share.
That is down 17% over the last year and down 87% over five years.
Its highest close in our data was $1.4B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $144.5M | $73.1M | $165.3M | −16% |
| 2025 | $171.7M | $145M | $521.1M | −61% |
| 2024 | $435.6M | $357.6M | $557.2M | −11% |
| 2023 | $486.8M | $296M | $588.8M | −13% |
| 2022 | $557.2M | $388.9M | $887.8M | −46% |
| 2021 | $1B | $977.2M | $1.4B | n/a |
Against its peers
Companies in Healthcare nearest Maxcyte's size, closest first, today.
| Company | Market cap |
|---|---|
| MXCTMaxcyte | $144.5M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| KEQUKewaunee Scientific | $94.9M |
| ELMDElectromed | $220.6M |
| ICCCImmucell | $93.1M |
| UTMDUtah Medical Products | $236.3M |
| INFUInfuSystem | $277.6M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| Peer median | $202.4M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Maxcyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.